DILTIAZEM Drug Patent Profile
✉ Email this page to a colleague
When do Diltiazem patents expire, and when can generic versions of Diltiazem launch?
Diltiazem is a drug marketed by Accord Hlthcare, Actavis Elizabeth, Actavis Labs Fl Inc, Alembic, Apotex, Biovail, Chartwell Rx, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Macleods Pharms Ltd, Mylan, Nesher Pharms, Novast Labs, Ph Health, Pharmobedient, Sun Pharm, Teva, Twi Pharms, Utopic Pharms, Valeant Pharms North, Zydus Pharms, Dr Reddys, Eugia Pharma, Hikma, Hikma Farmaceutica, Hospira, Intl Medication, Mylan Labs Ltd, Rising, Sagent, Amta, Sciegen Pharms, Apothecon, Chartwell Molecules, Edenbridge Pharms, Ivax Sub Teva Pharms, Teva Pharms, Zydus Lifesciences, Hq Spclt Pharma, and Exela Pharma. and is included in fifty-eight NDAs.
The generic ingredient in DILTIAZEM is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Diltiazem
A generic version of DILTIAZEM was approved as diltiazem hydrochloride by TEVA on May 31st, 1995.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DILTIAZEM?
- What are the global sales for DILTIAZEM?
- What is Average Wholesale Price for DILTIAZEM?
Summary for DILTIAZEM
| US Patents: | 0 |
| Applicants: | 40 |
| NDAs: | 58 |
| Drug Prices: | Drug price information for DILTIAZEM |
| Drug Sales Revenues: | Drug sales revenues for DILTIAZEM |
| DailyMed Link: | DILTIAZEM at DailyMed |
